Prognostic Impact of PD-L1 Expression in Malignant Salivary Gland Tumors as Assessed by Established Scoring Criteria: Tumor Proportion Score (TPS), Combined Positivity Score (CPS), and Immune Cell (IC) Infiltrate.
PD-L1
checkpoint inhibition
immuno-oncology
salivary gland carcinoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
03 Apr 2020
03 Apr 2020
Historique:
received:
03
03
2020
revised:
24
03
2020
accepted:
01
04
2020
entrez:
9
4
2020
pubmed:
9
4
2020
medline:
9
4
2020
Statut:
epublish
Résumé
Malignant neoplasms of the salivary glands are rare, and therapeutic options are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) scoring in salivary gland carcinomas (SGCs). In this retrospective study, we present a cohort of 94 SGC patients with full clinical follow-up. We included 41 adenoid cystic carcinomas (AdCC), 21 mucoepidermoid carcinomas (MEC), 16 acinic cell carcinomas (ACC), 12 adenocarcinomas, not otherwise specified (AC, NOS), 2 epithelial-myoepithelial carcinomas (EMC), one salivary duct carcinoma (SDC), and one carcinoma ex pleomorphic adenoma (CA ex PA). Subsequent histopathological analysis was performed with special emphasis on the composition of the immune cell infiltrate (B-/T-lymphocytes). We assessed PD-L1 (SP263) on full slides by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS) and immune cell (IC) score. We identified significantly elevated CD3+, TP, CP, and IC scores in AC, NOS compared to AdCC, MEC, and ACC. CPS correlated with node-positive disease. Moreover, AC, NOS displayed IC scores of 2 or 3 in the majority (67%) of cases (p = 0.0031), and was associated with poor prognosis regarding progression-free (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001). CPS correlated with strong nuclear or null p53 staining in AC, NOS but not in other SGCs. Long-lasting partial remission could be achieved in one AC, NOS patient who received Pembrolizumab as third-line therapy. The current study is the first to investigate the use of established scoring criteria for PD-L1 expression in malignant salivary gland tumors. Our findings identify unique characteristics for AC, NOS among the family of SGCs, as it is associated with poor prognosis and might represent a valuable target for immune checkpoint inhibition.
Sections du résumé
BACKGROUND
BACKGROUND
Malignant neoplasms of the salivary glands are rare, and therapeutic options are limited. Results from recently published studies indicate a possible use for checkpoint inhibition in a subset of patients, but there are no established criteria for programme cell death ligand 1 (PD-L1) scoring in salivary gland carcinomas (SGCs).
METHODS
METHODS
In this retrospective study, we present a cohort of 94 SGC patients with full clinical follow-up. We included 41 adenoid cystic carcinomas (AdCC), 21 mucoepidermoid carcinomas (MEC), 16 acinic cell carcinomas (ACC), 12 adenocarcinomas, not otherwise specified (AC, NOS), 2 epithelial-myoepithelial carcinomas (EMC), one salivary duct carcinoma (SDC), and one carcinoma ex pleomorphic adenoma (CA ex PA). Subsequent histopathological analysis was performed with special emphasis on the composition of the immune cell infiltrate (B-/T-lymphocytes). We assessed PD-L1 (SP263) on full slides by established scoring criteria: tumor proportion score (TPS), combined positivity score (CPS) and immune cell (IC) score.
RESULTS
RESULTS
We identified significantly elevated CD3+, TP, CP, and IC scores in AC, NOS compared to AdCC, MEC, and ACC. CPS correlated with node-positive disease. Moreover, AC, NOS displayed IC scores of 2 or 3 in the majority (67%) of cases (p = 0.0031), and was associated with poor prognosis regarding progression-free (PFS) (p < 0.0001) and overall survival (OS) (p < 0.0001). CPS correlated with strong nuclear or null p53 staining in AC, NOS but not in other SGCs. Long-lasting partial remission could be achieved in one AC, NOS patient who received Pembrolizumab as third-line therapy.
CONCLUSIONS
CONCLUSIONS
The current study is the first to investigate the use of established scoring criteria for PD-L1 expression in malignant salivary gland tumors. Our findings identify unique characteristics for AC, NOS among the family of SGCs, as it is associated with poor prognosis and might represent a valuable target for immune checkpoint inhibition.
Identifiants
pubmed: 32260165
pii: cancers12040873
doi: 10.3390/cancers12040873
pmc: PMC7226358
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
N Engl J Med. 2012 Jun 28;366(26):2455-65
pubmed: 22658128
Ann Oncol. 1996 Aug;7(6):640-2
pubmed: 8879381
Ann Oncol. 2017 Oct 1;28(10):2539-2546
pubmed: 28961851
Am J Surg Pathol. 2018 Feb;42(2):e11-e27
pubmed: 29076877
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Br J Cancer. 2019 May;120(10):1003-1006
pubmed: 30967647
Oncotarget. 2015 Jul 20;6(20):18224-37
pubmed: 26053092
J Exp Med. 2009 Dec 21;206(13):3015-29
pubmed: 20008522
BMC Cancer. 2018 Feb 6;18(1):156
pubmed: 29409471
Arch Pathol Lab Med. 2016 Aug 23;140(11):1243-1249
pubmed: 27552095
Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47
pubmed: 10758303
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Clin Cancer Res. 2020 Feb 15;26(4):837-845
pubmed: 31796519
Lancet Oncol. 2016 Jun;17(6):717-726
pubmed: 27157491
Mod Pathol. 2011 Sep;24(9):1248-53
pubmed: 21552211
Lancet Oncol. 2011 Aug;12(8):815-24
pubmed: 21147032
Oral Dis. 2002 Sep;8(5):229-40
pubmed: 12363107
Am J Clin Oncol. 2018 Feb 21;:
pubmed: 29462123
J Surg Oncol. 2016 Jul;114(1):36-43
pubmed: 27111278
Ann Oncol. 1994 Feb;5(2):113-7
pubmed: 8186153
Ann Oncol. 2012 Oct;23 Suppl 7:vii83-5
pubmed: 22997460
B-ENT. 2011;7(1):1-6
pubmed: 21563549
Curr Opin Oncol. 2010 May;22(3):200-5
pubmed: 20154619
Head Neck. 2004 Aug;26(8):681-92; discussion 692-3
pubmed: 15287035
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
Pathologe. 2018 Nov;39(6):498-519
pubmed: 30367225
Oral Oncol. 2001 Apr;37(3):315-22
pubmed: 11287288
Sci Rep. 2019 Sep 4;9(1):12724
pubmed: 31484986
Head Neck Pathol. 2017 Mar;11(1):55-67
pubmed: 28247227
Head Neck. 2019 Feb;41(2):269-280
pubmed: 30548929
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2899-906
pubmed: 19861510
JAMA Oncol. 2018 May 10;4(5):e180013
pubmed: 29543932
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977